<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04392960</url>
  </required_header>
  <id_info>
    <org_study_id>AC-015-IT</org_study_id>
    <nct_id>NCT04392960</nct_id>
  </id_info>
  <brief_title>Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis</brief_title>
  <official_title>Molecular, Magnetic Resonance, and Echocardiographic Imaging Combined With Biomarkers of Cardiac and Clonal Disease to Predict Survival and Assess Response to Therapy in Cardiac AL Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Policlinico S. Matteo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a systematic, combined, prospective assessment of the novel echographic, CMR,
      and PET imaging tools in newly-diagnosed patients with cardiac AL amyloidosis at baseline and
      after treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the prognostic relevance of advanced imaging variables.</measure>
    <time_frame>12 months after diagnosis</time_frame>
    <description>- for CMR: T1, T2, ECV, indexed volumes, mass, ejection fraction (EF);</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the prognostic relevance of advanced imaging variables.</measure>
    <time_frame>12 months after diagnosis</time_frame>
    <description>- for echocardiography: left ventricular wall thickness (mLVW), EF, 2D-GLS, midwall fractional shortening (mFS), and stroke volume index (SVI);</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the prognostic relevance of advanced imaging variables.</measure>
    <time_frame>12 months after diagnosis</time_frame>
    <description>- for F-PET: myocardial uptake score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of advanced imaging variables in response assessment.</measure>
    <time_frame>6 months after initiation of chemotherapy targeting the amyloid plasma cell clone</time_frame>
    <description>The same variables considered at baseline will be measured 6 months after initiation of chemotherapy targeting the amyloid plasma cell clone. Changes in these variables compared to baseline will be considered.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">69</enrollment>
  <condition>AL Amyloidosis</condition>
  <arm_group>
    <arm_group_label>18F-florbetaben PET-CT scans</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]Florbetaben</intervention_name>
    <description>Patients will undergo on the same day:
18F-florbetaben PET-CT scans. The dose to be injected intravenously (6 second/mL) will be 370 MBq (for a 70 Kg patient);
standard assessment of clonal and organ disease;
echocardiography;
cardiac magnetic resonance.
All the patients will undergo those evaluations at baseline and 6 months after treatment initiation.</description>
    <arm_group_label>18F-florbetaben PET-CT scans</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age more than 18;

          -  histological diagnosis of AL amyloidosis;

          -  measurable cardiac involvement as per current response criteria (i.e. NT-proBNP &gt;650
             ng/L);

          -  measurable hematologic disease (dFLC &gt;20 mg/L);

          -  adequate renal function (eGFR &gt;30 mL/min) in order to be safely administered
             gadolinium;

          -  absence of atrial fibrillation with uncontrolled heart rate;

          -  absence of implantable cardiac devices;

          -  absence of pulmonary amyloidosis histologically documented;

          -  plan to start anti-plasma cell chemotherapy;

          -  plan to assess response at the Pavia center after 6 months;

          -  have given written informed consent to participate.

        Exclusion Criteria:

          -  non-AL amyloidosis;

          -  NYHA class IV;

          -  PS-ECOG &gt;3;

          -  severe allergy to paramagnetic tracer;

          -  severe claustrophobia;

          -  pregnant or nursing women;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Giovanni Palladini, MD, PhD</last_name>
    <phone>+390382502994</phone>
    <email>segreteria.amiloidosi@smatteo.pv.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Carnevale Baraglia</last_name>
    <phone>+390382502994</phone>
    <email>a.carnevalebaraglia@smatteo.pv.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Palladini</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Palladini G, Barassi A, Klersy C, Pacciolla R, Milani P, Sarais G, Perlini S, Albertini R, Russo P, Foli A, Bragotti LZ, Obici L, Moratti R, Melzi d'Eril GV, Merlini G. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood. 2010 Nov 4;116(18):3426-30. doi: 10.1182/blood-2010-05-286567. Epub 2010 Jul 19.</citation>
    <PMID>20644111</PMID>
  </reference>
  <reference>
    <citation>Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004 Sep 15;22(18):3751-7.</citation>
    <PMID>15365071</PMID>
  </reference>
  <reference>
    <citation>Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, Foli A, Foard D, Milani P, Rannigan L, Hegenbart U, Hawkins PN, Merlini G, Palladini G. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013 Apr 25;121(17):3420-7. doi: 10.1182/blood-2012-12-473066. Epub 2013 Mar 11.</citation>
    <PMID>23479568</PMID>
  </reference>
  <reference>
    <citation>Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, Obici L, Bradwell AR, D'Eril GM, Fogari R, Moratti R, Merlini G. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood. 2006 May 15;107(10):3854-8. Epub 2006 Jan 24.</citation>
    <PMID>16434487</PMID>
  </reference>
  <reference>
    <citation>Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schönland S, Hegenbart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012 Dec 20;30(36):4541-9. doi: 10.1200/JCO.2011.37.7614. Epub 2012 Oct 22.</citation>
    <PMID>23091105</PMID>
  </reference>
  <reference>
    <citation>Mishra S, Guan J, Plovie E, Seldin DC, Connors LH, Merlini G, Falk RH, MacRae CA, Liao R. Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol Heart Circ Physiol. 2013 Jul 1;305(1):H95-103. doi: 10.1152/ajpheart.00186.2013. Epub 2013 Apr 26.</citation>
    <PMID>23624626</PMID>
  </reference>
  <reference>
    <citation>Diomede L, Rognoni P, Lavatelli F, Romeo M, del Favero E, Cantù L, Ghibaudi E, di Fonzo A, Corbelli A, Fiordaliso F, Palladini G, Valentini V, Perfetti V, Salmona M, Merlini G. A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis. Blood. 2014 Jun 5;123(23):3543-52. doi: 10.1182/blood-2013-10-525634. Epub 2014 Mar 24.</citation>
    <PMID>24665135</PMID>
  </reference>
  <reference>
    <citation>Weiss BM, Wong SW, Comenzo RL. Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis. Blood. 2016 May 12;127(19):2275-80. doi: 10.1182/blood-2015-11-681650. Epub 2016 Feb 23. Review.</citation>
    <PMID>26907632</PMID>
  </reference>
  <reference>
    <citation>Barros-Gomes S, Williams B, Nhola LF, Grogan M, Maalouf JF, Dispenzieri A, Pellikka PA, Villarraga HR. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System. JACC Cardiovasc Imaging. 2017 Apr;10(4):398-407. doi: 10.1016/j.jcmg.2016.04.008. Epub 2016 Sep 14.</citation>
    <PMID>27639764</PMID>
  </reference>
  <reference>
    <citation>Fontana M, Banypersad SM, Treibel TA, Abdel-Gadir A, Maestrini V, Lane T, Gilbertson JA, Hutt DF, Lachmann HJ, Whelan CJ, Wechalekar AD, Herrey AS, Gillmore JD, Hawkins PN, Moon JC. Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study. Radiology. 2015 Nov;277(2):388-97. doi: 10.1148/radiol.2015141744. Epub 2015 May 21.</citation>
    <PMID>25997029</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Matteo</investigator_affiliation>
    <investigator_full_name>GIOVANNI PALLADINI</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Amyloidosis</keyword>
  <keyword>Prognosis</keyword>
  <keyword>[18F]Florbetaben</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin Light-chain Amyloidosis</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

